<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105168</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A00373-52</org_study_id>
    <secondary_id>2007/1363</secondary_id>
    <nct_id>NCT02105168</nct_id>
  </id_info>
  <brief_title>Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment</brief_title>
  <acronym>MSN</acronym>
  <official_title>Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as
      chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of
      why those patients are relapsing using next generation sequencing to identify rare mutations
      and assessed their predictive value.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mutation rate on tumorous material</measure>
    <time_frame>Assessed at the time of inclusion</time_frame>
    <description>Assessed at the time of inclusion using tumorous material used for diagnosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Melanoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sample Tumorous biopsy Healthy material sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Optional</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumorous biopsy</intervention_name>
    <description>Optional</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Healthy material sample</intervention_name>
    <description>Optional</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cytological or histological diagnosis of SCLC, NSCLC or melanoma

          2. Patients age &gt;/= 18 years old

          3. Indication of treatment using platinum salts for lung cancer except for patient with
             NSCLC treated by surgery for whom platinum salts is not indicated

          4. If a biopsy is proposed, lesion lust be easily accessible

          5. Signed informed consent

        Exclusion Criteria:

          1. Patients unable to follow the protocol

          2. Consent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Besse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Besse, MD</last_name>
    <phone>0142114317</phone>
    <phone_ext>+33</phone_ext>
    <email>benjamin.besse@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Robert, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>caroline.robert@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Besse, MD</last_name>
      <phone>0142114317</phone>
      <phone_ext>+33</phone_ext>
      <email>benjamin.besse@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

